Genmab — November 2025
-
25/11 21:02 Euroinvestor "Genmab: Stemningen er vendt - Investoren Helge Larsen sætter ord på udviklingen af Genmab aktien" 2 min https://www.euroinvestor.dk/nyheder/genmab-stemningen-er-vendt
-
Blood: Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives https://ashpublications.org/blood/article/146/22/2617/548279/Better-together-epcoritamab-boosts-R2-in-FL
-
Impressive: The efficacy appeared impressive: ORR 96% and CR 88% that were maintained even in patients with high-risk features. Minimal residual disease negativity rate was 86%. Survival outcomes at 2 years look favorable as well: remaining in CR for the duration of the study, 82% = KYSO...
-
-
Så vi kan forvente at Kina kommer ind fra højre med mange præperater vi evt. skal konkurrere med
-
Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of DLBCL https://onlinelibrary.wiley.com/doi/10.1002/jha2.70186
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind